Across two publications by Alessi et al., whether the co-mutated NSCLC patients were treated in the first line with CIT or in ≥ 2nd line with single-agent ICI in combination with CTLA-4, the patients had statistically worse OS [21,22]. This evidence concerns the gene CTLA4 and non-small cell lung carcinoma.